Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and cardiovascular outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Sok Cin Tye, Niels Jongs, Steven G. Coca, Johan Sundström, Clare Arnott, Bruce Neal, Vlado Perkovic, Kenneth W. Mahafey, Priya Vart and Hiddo. J. L. Heerspink

Journal title: Cardiovascular Diabetology

Journal number: 21, Article number: 194 (2022)

Journal publisher: BioMed Central

Published year: 2022

DOI identifier: 10.1186/s12933-022-01619-0

ISSN: 1475-2840